secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001193125-23-292306
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine initial Phase 1b/2 data: DISC-0974 shows dose-dependent hepcidin reduction and Hb improvement in MF anemia
--------------------------------------------------------------------------------

- DISC-0974 reduced serum hepcidin >75% and increased serum iron >75% at 28 mg dose.
- 57% (4/7) of evaluable non-transfusion-dependent patients achieved ≥1.5 g/dL hemoglobin increase.
- One of two transfusion-dependent patients achieved transfusion independence per Gale Criteria.
- Hematologic activity observed regardless of concomitant JAK inhibitor use; drug generally well-tolerated.
- Data presented at ASH 2023; dose escalation ongoing with 11 evaluable subjects from three dose levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523292306/0001193125-23-292306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523292306/d644657d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer